Last updated: February 25, 2026
What is the scope of JP5735200?
JP5735200 protects a pharmaceutical composition comprising a compound with specific stereochemistry and its intended use. The patent broadly covers:
- Active Ingredient: A class of compounds, specifically 1,4-dihydropyridine derivatives with defined substituents.
- Pharmaceutical Composition: Compositions containing these derivatives for treating cardiovascular conditions, particularly hypertension.
- Method of Use: Methods for preventing or reducing symptoms related to hypertension using the specified compounds.
The scope emphasizes compounds with particular structural features, including the stereochemistry at certain positions, extending protection to close analogues sharing core characteristics.
What are the key claims?
Claim breakdown:
| Claim Type |
Content |
Scope |
| Independent Claims |
- Compound claim: A 1,4-dihydropyridine derivative with specified substitutions, including stereochemistry.
- Use claim: Use of the compound for treating hypertension or cardiovascular disorders.
- Composition claim: Pharmaceutical formulations containing the compound. |
Covers specific stereoisomers and analogs of the base compound, emphasizing their use in therapy. Protects both the compound and its pharmaceutical formulations. |
| Dependent Claims |
- Variations in substituents on the core structure.
- Specific stereochemistry configurations.
- Different formulation types (e.g., tablets, injections). |
Narrower rights, specifying preferred embodiments and formulations, but collectively expanding the patent's coverage. |
Claim elements:
- Stereochemistry at the 3- and 5-positions in the dihydropyridine ring.
- Definitions of substituents such as aromatic groups, alkyl, or halogen groups.
- Use claims cover methods of reducing blood pressure using the compound.
Patent landscape and prior art considerations
Related patents and applications:
- Neighboring patents: Similar patents exist in Japan and globally covering dihydropyridine derivatives for hypertension, especially originating from major pharmaceutical firms.
- Prior art references: Patent family documents and scientific publications prior to the filing date (likely around late 2000s or early 2010s) describe similar calcium channel blockers.
Patent family overview:
| Patent Family |
Filing Dates |
Jurisdictions |
Scope Similarities |
Key Differences |
| JP patent family |
Filing around mid-2000s |
Japan, US, EP, China |
Similar compounds and therapeutic methods |
Specific stereochemistry and formulations proprietary to JP5735200 |
Patent expirations and freedom-to-operate:
- The patent was filed in Japan during the mid-2000s with a standard 20-year term from filing (~2005), likely expiring around 2025.
- Competitive landscape includes other compounds like amlodipine, nifedipine, and felodipine, which are older calcium channel blockers.
Critical analysis
- The claim scope appears to be focused on specific stereoisomeric forms, which may limit generic competition if the stereochemistry is critical for efficacy.
- The breadth of the composition claims underscores an effort to protect not only the compound but also pharmaceutical preparations.
- Prior art referencing similar calcium channel blockers may impact the novelty unless the stereochemistry or specific substituents confer non-obvious advantages.
- The expiration date implicates potential generic entry from around 2025, unless patent term adjustments or extensions apply.
Summary
JP5735200 protects a class of stereochemically defined dihydropyridine derivatives for use in antihypertensive therapy. Its claims extend to compounds, formulations, and methods of treatment, with a scope specific to certain stereoisomers. The patent landscape includes similar compounds and methods, but the specificity of stereochemistry and structural features provides a distinct rights position. The patent is approaching expiration, opening the landscape for generic development.
Key Takeaways
- JP5735200 offers protection for specific stereoisomers of dihydropyridine derivatives used in hypertension.
- The claims are comprehensive, covering compounds, formulations, and therapeutic methods.
- Competitive landscape involves established calcium channel blockers; patent timing suggests imminent patent expiry.
- Narrow claim scope focused on stereochemistry may influence freedom to operate for generic challengers.
- Patent landscape includes several related patents with overlapping structural and functional claims.
FAQs
1. What is the main therapeutic target of JP5735200?
It aims at treating hypertension and cardiovascular conditions via calcium channel blockade.
2. How does the stereochemistry influence the patent scope?
Claims specify stereoisomeric forms, which may be critical for activity, limiting design-around options.
3. When is the patent expected to expire?
Expected around 2025, assuming no term adjustments or extensions.
4. Can similar compounds without the specified stereochemistry infringe?
Likely not if stereochemistry is patent-claimed; non-stereospecific compounds may avoid infringement.
5. How does JP5735200 compare with global patents on calcium channel blockers?
It is more focused on specific stereoisomeric forms, providing narrower but potentially stronger protection within those bounds.
References
- Japanese Patent Office (JPO). Patent document JP5735200.
- WIPO. Patent landscape report on dihydropyridine derivatives.
- Patent comparison reports on calcium channel blockers.
- European Patent Office (EPO). Patent family documents for similar calcium channel blocker compounds.
- U.S. Patent and Trademark Office (USPTO). Related patent filings and prior art references.
